Abstract
Recently, a role of anti-Müllerian hormone (AMH), a member of the transforming growth factor-β family, has been suggested as an ovarian reserve marker as well as regulator of folliculogenesis and oocyte maturation. Gonadotropin releasing hormone agonists (GnRHa) and antagonists (GnRHant) have widely been used for the prevention of premature LH surges during controlled ovarian hyperstimulation (COH) for IVF-ET. Although it is known that there are no significant differences in pregnancy and implantation rates, other COH outcomes such as estradiol (E2) levels on hCG day and number of oocytes retrieved are reported to be different between the two protocols.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
